Literature DB >> 10686462

Critical illness polyneuropathy. A 2-year follow-up study in 19 severe cases.

M de Sèze1, H Petit, L Wiart, J P Cardinaud, E Gaujard, P A Joseph, J M Mazaux, M Barat.   

Abstract

Critical illness polyneuropathy (CIP) is a reported cause of varying degrees of neuromuscular weakness in patients with multiple organ failure. Little is known concerning predictive factors of neurological recovery. The critical care conditions, neurological explorations and 2-year clinical follow-up of 19 patients who suffered from severe forms (quadriplegia or quadriparesis) of CIP were analyzed. Characteristics of patients who recovered clinically were compared with those of patients who did not. Two patients died within 2 months, 11 recovered completely, 4 remained quadriplegic and 2 remained quadriparetic. All patients suffered from sepsis, multiple organ dysfunction syndrome and a catabolic state before the onset of CIP. Outcome appears difficult to predict with clinical or electrophysiological data. Three parameters were significantly correlated with poor recovery: longer length of stay in the critical care unit, longer duration of sepsis and greater body weight loss. A relationship seems to exist between the severity of CIP and that of sepsis and its associated hypercatabolism. The favorable outcome usually attributed to CIP must be reconsidered. The authors recommend aggressive measures against sepsis to limit CIP and its sequelae. Copyright 2000 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2000        PMID: 10686462     DOI: 10.1159/000008137

Source DB:  PubMed          Journal:  Eur Neurol        ISSN: 0014-3022            Impact factor:   1.710


  17 in total

1.  Neuromuscular alterations in the critically ill patient: critical illness myopathy, critical illness neuropathy, or both?

Authors:  Nicola Latronico
Journal:  Intensive Care Med       Date:  2003-09       Impact factor: 17.440

Review 2.  [Intensive care unit-acquired weakness in the critically ill : critical illness polyneuropathy and critical illness myopathy].

Authors:  K Judemann; D Lunz; Y A Zausig; B M Graf; W Zink
Journal:  Anaesthesist       Date:  2011-10       Impact factor: 1.041

Review 3.  Critical illness polyneuropathy and myopathy in the intensive care unit.

Authors:  Wolfgang Zink; Rainer Kollmar; Stefan Schwab
Journal:  Nat Rev Neurol       Date:  2009-07       Impact factor: 42.937

Review 4.  Intensive care unit-related generalized neuromuscular weakness due to critical illness polyneuropathy/myopathy in critically ill patients.

Authors:  Efstratios Apostolakis; Nikolaos A Papakonstantinou; Nikolaos G Baikoussis; George Papadopoulos
Journal:  J Anesth       Date:  2014-07-01       Impact factor: 2.078

5.  Critical illness myopathy in a cervical spine-injured patient.

Authors:  Franz K Pencle; Nelofar Kureshi; Timothy Benstead; Sean D Christie
Journal:  Spinal Cord Ser Cases       Date:  2016-07-14

Review 6.  Bench-to-bedside review: mobilizing patients in the intensive care unit--from pathophysiology to clinical trials.

Authors:  Alex D Truong; Eddy Fan; Roy G Brower; Dale M Needham
Journal:  Crit Care       Date:  2009-07-13       Impact factor: 9.097

7.  Critical illness polyneuropathy in patients with major burn injuries.

Authors:  Queenie Chan; Karl Ng; John Vandervord
Journal:  Eplasty       Date:  2010-11-19

8.  Inactivation of sodium channels underlies reversible neuropathy during critical illness in rats.

Authors:  Kevin R Novak; Paul Nardelli; Tim C Cope; Gregory Filatov; Jonathan D Glass; Jaffar Khan; Mark M Rich
Journal:  J Clin Invest       Date:  2009-05       Impact factor: 14.808

Review 9.  Clinical review: Critical illness polyneuropathy and myopathy.

Authors:  Greet Hermans; Bernard De Jonghe; Frans Bruyninckx; Greet Van den Berghe
Journal:  Crit Care       Date:  2008-11-25       Impact factor: 9.097

10.  What patients think about ICU follow-up services: a qualitative study.

Authors:  Suman Prinjha; Kate Field; Kathy Rowan
Journal:  Crit Care       Date:  2009-04-01       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.